fig1

Combating CHK1 resistance in triple negative breast cancer: EGFR inhibition as potential combinational therapy

Figure 1. Erlotinib co-exposure with prexasertib synergistically enhanced cell killing. Viability of 3D cultures of MDA-231 (A) and MDA-468 (B) after exposure to prexasertib, erlotinib, and combinations of erlotinib and prexasertib; the combination index (CI) showed synergistic interaction (CI < 1) of erlotinib and prexasertib in both MDA-231 and MDA-468 (C).

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/